Abstract 1603: Discover potent and functional human antibodies against a new B7-family member target for cancer immunotherapy

Author(s):  
Xiaodong Wu ◽  
Yongqiang Wang ◽  
Xiaocheng Lv ◽  
Fei Chen ◽  
Yun He ◽  
...  
Cell Reports ◽  
2014 ◽  
Vol 9 (3) ◽  
pp. 1089-1098 ◽  
Author(s):  
Hyungjun Jeon ◽  
Vladimir Vigdorovich ◽  
Sarah C. Garrett-Thomson ◽  
Murali Janakiram ◽  
Udupi A. Ramagopal ◽  
...  

2012 ◽  
Vol 64 (8) ◽  
pp. 571-590 ◽  
Author(s):  
Martin F. Flajnik ◽  
Tereza Tlapakova ◽  
Michael F. Criscitiello ◽  
Vladimir Krylov ◽  
Yuko Ohta

Immunity ◽  
2003 ◽  
Vol 18 (6) ◽  
pp. 863-873 ◽  
Author(s):  
Durbaka V.R Prasad ◽  
Sabrina Richards ◽  
Xoi Muoi Mai ◽  
Chen Dong

2008 ◽  
Vol 86 (Supplement) ◽  
pp. 511
Author(s):  
J Popoola ◽  
J Yang ◽  
A Vidhyadharan ◽  
M Sayegh ◽  
A Chandraker

2021 ◽  
Vol 19 ◽  
pp. 205873922110005
Author(s):  
Liyun Zhou ◽  
Zhenhua Jiang ◽  
Jing Gu ◽  
Wenhui Gu ◽  
Shuangyin Han

Digestive system cancers (DSC) are the most common cancers worldwide and often associated with poor prognosis because of their characteristics of invasive and metastatic. Thus, it is particularly necessary to find novel molecular targets for early diagnosis, as well as targeted treatment of DSC. B7-H3, which was previously referred to as a modulatory ligand that regulate T-cell-mediated immune reaction, is a B7-family member of co-stimulatory biomolecules, and in recent years it was found that its concentration was remarkably up modulated in serum, as well as tissues of DSC patients. Numerous studies have documented that B7-H3 has a vital function in the DSC. Herein, we summarize the current literature on diagnosis and prognosis potential of B7-H3 in DSC including those of the esophagus, gastric, liver, pancreas, and colon.


2017 ◽  
Vol 22 (4) ◽  
pp. 175-179
Author(s):  
Andrei I. Chapoval ◽  
S. V Podlesnykh ◽  
E. A Kolosova ◽  
D. N Shcherbakov

Members of B7-CD28 family ligands and receptors play the important role in the co-stimulation and inhibition of the T-cell mediated immune response. Blocking of the B7 family molecules inhibiting the immune response (also called immunological checkpoints), CTLA4 and PD-1 / PD-L1 promoted to important therapeutic achievements in cancer immunotherapy and improved survival of cancer patient. The recent discovery of new B7 family molecules (such as B7-H3 [CD276], B7-H4 [B7S1 / B7x / Vtcn1], B7-H5 [VISTA / PD-1H / GI24], B7-H6 and B7-H7 [HHLA2]) has expanded therapeutic possibilities for the management of cancer patients. In this article, we discuss the clinical application of known blockers of immunological checkpoints and the prospects for the use of newly discovered molecules.


Sign in / Sign up

Export Citation Format

Share Document